Intravitreal injection of bevacizumab in Eales disease.
OBJECTIVE
To report a case of presumed Eales disease that showed regression of retinal neovascularization after the use of intravitreal bevacizumab.


METHODS
Retrospective, interventional case report.


METHODS
Broad retinal neovascularization in a patient with presumed Eales disease did not regressed despite adequate photocoagulation treatment, and bevacizumab (1.25 mg) was injected intravitreally. The patient was followed up for 1 year.


RESULTS
One week after injection, fluorescein angiography demonstrated dramatic regression of retinal neovascularization. After 12-months, visual acuity was improved and no signs of recurrence were observed.


CONCLUSIONS
Intravitreal bevacizumab may be effective as an adjunctive treatment of retinal neovascularization in patients with Eales disease.
Küçükerdönmez
Cem
C
Department of Ophthalmology, Baskent University Faculty of Medicine, Ankara, Turkey. drcemk@hotmail.com
Akova
Yonca A
YA
Yilmaz
Gürsel
G
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D012171:Retinal Vessels; D012189:Retrospective Studies; D016896:Treatment Outcome; D014657:Vasculitis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab